NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
ZEPBOUND KWIKPEN (tirzepatide) by Eli Lilly and Company is g-protein-linked receptor interactions [moa]. Approved for glucose-dependent insulinotropic polypeptide receptor agonist [epc]. First approved in 2023.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEPBOUND KWIKPEN (tirzepatide) is a subcutaneous GIP receptor agonist approved in November 2023 for chronic weight management in adults with obesity or overweight with weight-related conditions. It works by activating G-protein-linked receptors to enhance glucose-dependent insulin secretion and satiety signaling. The KWIKPEN formulation represents a device innovation on Eli Lilly's tirzepatide platform.
Growth13.0 years to LOE
Early-stage growth product with 13+ years of patent protection; teams are scaling commercial infrastructure to capture obesity market expansion.
Mechanism of Action
G-Protein-linked Receptor Interactions
Pharmacologic Class:
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Started Aug 2026
224 enrolled
Obesity and Overweight
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
Started May 2026
30 enrolled
Psoriatic ArthritisOsteoarthitisKnee+12 more
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
Started Feb 2026
344 enrolled
Diabetes Mellitus, Type 2ObesityOverweight
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Started Feb 2026
60 enrolled
Idiopathic Intracranial Hypertension (IIH)
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
Started Jan 2026
40 enrolled
Diabetes Mellitus, Type 2OverweightObesity
Worked on ZEPBOUND KWIKPEN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.